Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Sees Large Decrease in Short Interest

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the target of a large decrease in short interest in the month of May. As of May 29th, there was short interest totaling 39,018 shares, a decrease of 73.7% from the May 14th total of 148,551 shares. Based on an average daily trading volume, of 4,357,454 shares, the days-to-cover ratio is presently 0.0 days.

Lakewood-Amedex Biotherapeutics Price Performance

Shares of LABT traded down $0.04 during trading hours on Thursday, hitting $0.72. The company had a trading volume of 164,681 shares, compared to its average volume of 3,041,669. Lakewood-Amedex Biotherapeutics has a one year low of $0.59 and a one year high of $9.82.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.